EconoMic iMpact of changEs in nicu VEntilation stratEgiEs With thE aDVEnt of nEW noninVasiVE VEntilation tEchniquEs: a rEViEW anD proposED assEssMEnt fraMEWork for high floW thErapy (hft) as a routinE rEspiratory support paraDigM

benefit for diabetes patients who do not require insulin. Under the Ontario Public Drug Programs (OPDP), these patients have a 200-400 strip/year limit, whereas patients who require insulin can receive up to 3,000 strips annually. The policy intent was not to change BGTS utilization for insulin patients; however, concerns exist around potential negative impacts on diabetes management. The objective of this analysis is to quantify the impact of this new BGTS utilization policy in Ontario across diabetes patients based on their diabetes treatment. Methods: All patients who received BGTS coverage from the OPDP during July 2012 – September 2014 were selected for analysis using the IMS Brogan OPDP Database. Annual BGTS utilization prior to the policy change (July 2012 – June 2013) was then compared to annual BGTS utilization following Ontario’s coverage limit (October 2013 September 2014). Patients were categorized into one of four cohorts based on their diabetes medication history: ‘insulin only’,’ insulin + oral anti-diabetic (OAD)’, ‘OAD’, or ‘neither’. Changes in utilization patterns were assessed for each cohort. Results: 422,525 patients were identified for the pre-period, and 422,154 patients were identified for the post-period. Overall BGTS unit volume declined from 192M to 147M (-24%) following the OPDP policy change. On average, the number of BGTS per patient per year decreased for ‘OAD ’ and ‘neither’ cohorts by 42% and 54%, respectively. Impact to patients managing diabetes with insulin was minimal: ‘insulin only’ (-1%) and ‘insulin + OAD’ (-2%). ConClusions: BGTS utilization markedly decreased in diabetes patients not managed with insulin; test strip utilization was marginally impacted for patients using insulin.